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SUMMARY. Chronic hepatitis C virus (HCV) infections with
genotype 2 or 3 are associated with favourable sustained
virologic response (SVR) rates. However, genotype 3 may
respond less well. We reassessed all treatment-naive patients
with genotype 2 and 3 participating in a large expanded-
access, non-randomized, open-label trial, evaluating 180lg
pegylated interferon (peg-IFN) alpha-2a (40kD) once weekly
and 800 mg/day ribavirin for 24–48 weeks. Factors mea-
sured prior to initiation of antiviral therapy were considered
in the multiple logistic regression model for predicting SVR.
In total, 180 patients were analysed of which 72 (40%) were
infected by genotype 2 and 108 (60%) genotype 3. The
baseline characteristics between patients infected by geno-
type 2 or 3 were no different including the distribution of
hepatic ﬁbrosis stages by METAVIR score. Overall SVR was
lower in those patients infected with genotype 3. The sig-
niﬁcant multivariate predictors of lack of SVR were hepatic
ﬁbrosis (P = 0.014) and genotype 3 (P = 0.030). The neg-
ative impact of cirrhosis (METAVIR score F4) on treatment
response was more evident among subjects with genotype 3
than those with genotype 2 (P = 0.027). There is signiﬁcant
interaction between cirrhosis and genotype 3 leading to a
poor antiviral response in such patients requiring an alter-
nate management strategy. This ﬁnding should be conﬁrmed
in a larger population.
Keywords: cirrhosis, genotype, hepatic ﬁbrosis, hepatitis C
virus, interferon therapy, outcomes, sustained viral response.
INTRODUCTION
Antiviral therapy for the treatment of hepatitis C virus (HCV)
infection has evolved over time from interferon monotherapy
to combination therapy with interferon and ribavirin (RBV),
to the present standard of care, namely pegylated interferon
(peg-IFN) and ribavirin [1–7]. Several factors have become
evident as predictors of response to antiviral therapies;
however, none are more powerful than genotype. Genotype
2 and 3 infections are consistently associated with signiﬁ-
cantly higher rates of sustained virological response (SVR)
compared with genotype 1 infections [8–12]. Although the
precise biological explanation for the difference in sustained
virological response (SVR) rates among genotype 1 vs
genotype 2 and 3 remains elusive, it has been clearly dem-
onstrated that viral kinetics in response to interferon therapy
differ between the two groups in both the ﬁrst and second
phase of viral decline. The viral decline among genotype 2
and 3 infections is up to eight times faster than that of
genotype 1 [13,14]. This rapid virological response to ther-
apy has prompted the development of shorter courses of
therapy for genotype 2 and 3 from the traditional 48 weeks
to as few as 12–16 weeks in investigative protocols, when-
ever a rapid virological response (RVR) is achieved with HCV
polymerase chain reaction (PCR) negativity after 4 weeks of
therapy [9,11,12].
As a result of their favourable antiviral response, genotype
2 and 3 infections are frequently grouped together when the
results of clinical trials are evaluated and hence also in
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however, have reported that genotype 3 infections are
associated with lower rates of SVR than genotype 2 infec-
tions in clinical trials of treatment with pegylated interferon
and ribavirin [8,9,11,12]. Although genotype has been a
consistent factor associated with treatment response among
genotype 2 and 3 patients, there is little consensus regarding
other factors associated with differential response between
patientswithgenotype2andgenotype3.Dalgardetal.[9]ina
pilot study of a short course (14 weeks) of therapy with peg-
IFN alpha-2b and RBV demonstrated that the lack of bridging
ﬁbrosis/cirrhosiswasanimportantfactorassociatedwithSVR
in a mixed genotype 2/3 cohort of patients. Von Wagner
etal.[12]andZeuzemetal.[8]foundthatahighbaselineviral
load but not ﬁbrosis was associated with a lack of SVR, espe-
cially among patients with genotype 3 [8,12]. Finally, astudy
by Mangia et al. [11] did not identify any factors other than
genotypethatpredictedresponseamongthestudypopulation
consisting primarily of patients with genotype 2.
Response to antiviral therapy is not the only differentiat-
ing characteristic between the two genotypes. Genotype 3
has long been known to be associated with hepatic steatosis
independent of other factors such as body mass index (BMI)
and alcohol intake, whereas no such relationship exists be-
tween hepatic steatosis and genotype 2 [15–18]. Genotype 3
has also been demonstrated to have considerable differences
in E2 glycoprotein compared with genotype 1, which appears
to preferentially induce apoptosis, possibly promoting hepa-
tic ﬁbrogenesis [19,20]. The most striking evidence demon-
strating the direct impact of genotype 3 infection on
hepatocytes is the reversal of steatosis with successful an-
tiviral therapy [21,22].
Thus genotype 2 and 3 appear to behave differently in the
host as well as in their response to antiviral therapy. The aim
of our study was to conﬁrm the difference in SVR among
genotype 2- and genotype 3-infected HCV patients and
determine factors associated with antiviral response to peg-
IFN alpha-2a and RBV, as well as exploring interactions
between these factors and genotype.
PATIENTS AND METHODS
Study population
This study is a re-analysis of a large Canadian expanded-
access, multi-centred, non-randomized, open-label phase
III-B trial evaluating 180 lg 40-kDa peg-IFN (Pegasys
 ;
F. Hoffman-La Roche Ltd, Pharamaceuticals Division,
Granzacherstrasse, Basel, Switzerland) once weekly and
800 mg/day RBV (Copegus
 ; F. Hoffman-La Roche Ltd,
Pharamaceuticals Division, Granzacherstrasse, Basel,
Switzerland) for 24 or 48 weeks for the therapy of chronic
hepatitis C [23,24]. The patients were allocated at the
discretion of the site investigator, to either a planned 24 or
48 weeks with peg-IFN and RBV. At the time of the Canadian
study, the results of Hadziyannis et al. regarding the equiv-
alence of SVR by 24- or 48-week therapy in genotype 2 and 3
had not been published [10]. Our study speciﬁcally examined
the differential treatment effect of genotype 2 and 3 infections
in those naı ¨ve to antiviral therapy who underwent at least
12 weeks of therapy. The protocol has been described in
detail elsewhere [23,24]. Brieﬂy, between April 2001 and
June 2004, patients were recruited from 18 sites across
Canada according to standard eligibility criteria which
included positive HCV antibody, positive qualitative
HCV-RNA, lack of co-infection with hepatitis B or human
immunodeﬁciency virus (HIV), absence of another cause of
liver disease and a liver biopsy within the past year. Liver
biopsy samples were analysed by local expert pathologists
and staged according to the previously validated METAVIR
ﬁbrosis score [25]. In this study, we used stringent deﬁnition
of cirrhosis requiring histological ﬁnding of regenerative
nodule surrounded by ﬁbrosis (F4 ﬁbrosis score).
Sustained virological response was based on a negative
qualitative HCV PCR result (COBAS Amplicor HCV Test v
2.0; F. Hoffman-La Roche Ltd, Pharmaceuticals Division,
Grenzacherstrasse, Basel, Switzerland) 24 weeks after the
end of the prescribed treatment duration (i.e. 48 weeks in
the 24-week treatment arm and 72 weeks in the 48-week
treatment arm). If HCV PCR testing was not available
24 weeks after completion of treatment, the patient was
declared a treatment failure.
Genotype was determined by the Bayer VERSANT HCV
Genotype Assay (Inno Lipa, Innogenetics, Technologiepark,
Gent, Belgium). All HCV virology analyses were performed at
the British Columbia Centre of Disease Control Virology
Laboratory, Vancouver, BC, Canada.
Statistical analysis
Only factors available prior to the initiation of antiviral
therapy were considered as potential predictors in the anal-
ysis (age, gender, BMI, baseline viral load, genotype and
hepatic ﬁbrosis). Univariate associations between SVR and
categorical predictors were assessed with Fishers exact test
(Wilcoxons rank-sum test for numeric predictors). Unlike
previous studies, the variables entered into the multiple
logistic regression (MLR) model were analysed as either
continuous or ordinal variables and not grouped into
dichotomous variables. This approach was used, as cut-off
points for variables such as viral load and METAVIR ﬁbrosis
score are not known a priori. Genotype and factors potentially
associated with SVR on univariate analysis (P < 0.15) were
then entered into the MLR model. Thereafter, the differential
inﬂuence of predictor variables among genotype was assessed
graphically and if required statistically by modelling the
cross-product of the variable of interest with genotype in an
MLR model. The alpha level of signiﬁcance for a two-tailed
test was considered to be 0.05. All statistical analyses were
performed using SAS v. 9.1 (SAS Institute, Cary, NC, USA).
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One hundred and eighty patients met the eligibility criteria.
Baseline data were complete for all patients except for one
(genotype 2) who did not have data for BMI. Baseline
characteristics of the 180 patients are presented in Table 1.
There were 126 (70%) patients assigned to the 24-week
treatment group and 54 (30%) to the 48-week group.
Treatment was discontinued before week 12 in 12 (7%)
patients, ﬁve (7%) with genotype 2 and seven (6%) with
genotype 3, because of either poor tolerance or adverse
events. There was no difference among patients infected with
genotype 2 or 3.
Another 12 (7%) patients, three (4%) infected with
genotype 2 and nine (9%) infected with genotype 3, either
dropped out or did not submit a blood sample to the central
laboratory for the ﬁnal determination of SVR 24 weeks after
completion of therapy. These patients were all considered
treatment failures and assigned to the no SVR category.
Among the 67 genotype 2 patients who had undergone
at least 12 weeks of therapy, 54 (81%) achieved an
SVR compared with 71 of 101 (70%) genotype 3 patients.
Factors signiﬁcantly associated with SVR in the whole
cohort of 180 patients on univariate analysis included
METAVIR ﬁbrosis score (P = 0.004), BMI (P = 0.018) and
treatment group (P = 0.033). As shown in Table 2, age,
gender and baseline log viral load were not signiﬁcant on
univariate analysis.
Genotype, METAVIR ﬁbrosis score, treatment group and
BMI were then assessed in an MLR model with ﬁbrosis score
considered as a categorical variable with values from 0 to 4.
In this initial model, genotype and hepatic ﬁbrosis were the
only independent variables signiﬁcantly associated with SVR.
The odds ratios associated with lack of SVR are presented in
Table 3. Genotype 3 infections had an overall 2.29 greater
odds for lack of SVR compared with genotype 2 infections,
while a ﬁbrosis score of F3 orF4 compared withF0 had 10.90
and 27.90 greater odds for lack of SVR, respectively. Those
assigned to the 48-week treatment duration also had lower
SVR; however, when the 12 subjects who withdrew early
(before 12 weeks of therapy) were removed from the analysis
this factor lost signiﬁcance (P = 0.167).
In order to further explore the possibility of an interaction
between genotype and ﬁbrosis, SVR rates were plotted
according to genotype and METAVIR ﬁbrosis score. Figure 1
demonstrates that patients with genotype 3 and cirrhosis
had lower rates of SVR compared with genotype 2 patients
with cirrhosis. Patients with genotype 3 and cirrhosis had an
SVR rate of 17% (2/12) compared with 78% (7/9) among
those with genotype 2 and cirrhosis (P < 0.001; 95% CI for
difference 0.27–0.95). This was assessed statistically by
constructing an MLR model including genotype, cirrhosis
(presence/absence), treatment group and BMI as well as the
cross-product of genotype and cirrhosis. This MLR model
demonstrated that there is a signiﬁcant interaction between
cirrhosis and genotype, where genotype is an important
Table 1 Characteristics of study popula-
tion according to genotype
Characteristics
Genotype 2
(n = 72)
Genotype 3
(n = 108)
Genotype 2 and 3
(n = 180)
Female 30 (42) 37 (34) 67 (37)
Age (years)
a 48 40 44
BMI (kg/m
2)
a,b 28 27 27
log10 viral load (IU/L)
a 5.51 5.82 5.70
METAVIR score
0 5 (7) 14 (13) 19 (11)
1 18 (25) 26 (24) 44 (24)
2 27 (38) 37 (34) 64 (36)
3 13 (18) 19 (18) 32 (18)
4 9 (12) 12 (11) 21 (11)
Treatment duration
24 weeks 45 (62) 81 (75) 126 (70)
48 weeks 27 (38) 27 (25) 54 (30)
Early withdrawal
c 5 (7) 7 (6) 12 (7)
Late drop out
d 3 (4) 9 (9) 12 (7)
Values in parentheses are percentages.
aMean.
bOne patient (genotype 2) did not have data of pretreatment BMI available.
cThese patients withdrew before week 12 either due to poor tolerance or adverse
events.
dThese patients dropped out or did not submit blood sample for SVR assessment
24 weeks after completing therapy.
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(P = 0.027). Those patients with genotype 3 and cirrhosis
do worse than those with genotype 2 and cirrhosis. This
difference was not due to adherence as the latter ﬁnding
remained intact even when data were reanalysed after
excluding the 12 patients who withdrew early (before
12 weeks of therapy) or the 12 patients who did not submit
a blood sample for determination of SVR 24 weeks after
completing the treatment course.
DISCUSSION
Therapy with peg-IFN alpha 2a and ribavirin 800 mg/day
achieves SVR rates in over 70% when those with genotype 2
and 3 infections are treated as a homogenous group [10].
The remainder either does not respond to antiviral therapy
or relapses after cessation of therapy. This study demon-
strates that there was a signiﬁcant interaction between cir-
rhosis and genotype 3 infections. The SVR rate among
genotype 2 infections with cirrhosis was 78% compared with
17% among those patients with genotype 3 and cirrhosis.
Our ﬁndings show the negative effect on treatment response
of advanced ﬁbrosis, especially cirrhosis, is limited to geno-
type 3 infections with no demonstrable effect on genotype 2.
The inﬂuence of hepatic ﬁbrosis on responsiveness to an-
tiviral therapy has been previously demonstrated in one
other clinical trial involving patients with genotype 2 and 3
infections [9]. Other investigators, however, have not found
the same association between hepatic ﬁbrosis and SVR
among genotypes 2 and 3 [8,11,12].
There are several possible explanations for the discrepancy
between our results and those of other trials of peg-IFN for
the treatment of genotype 2 and 3. Similar to the study by
Dalgard et al. [9], more than a quarter of our patients had
advanced ﬁbrosis (17% F3 and 11% F4); this compares well
Table 3 Multivariate analysis of factors associated with lack
of SVR
Variable Odds ratio (95% CI) p-value
Genotype
21
3 2.29 (1.08–4.83) 0.030
METAVIR ﬁbrosis score 0.014
01
1 5.50 (0.63–48.32) 0.124
2 7.58 (0.91–63.19) 0.061
3 10.90 (1.23–96.40) 0.032
4 27.90 (2.93–265.73) 0.004
BMI
a 1.07 (0.99–1.16) 0.102
aOne patient did not have data on BMI available and was not
included in the MLR model.
Table 2 Univariate analysis of factors at baseline potentially
associated with sustained virological response
SVR No SVR p-value
Age (years)
a 44 43 0.595
c
Gender 0.315
d
Female 50 (40) 17 (31)
Male 75 (60) 38 (69)
log10 viral load (IU/L)
a 5.68 5.75 0.861
c
Genotype 0.248
d
2 54 (43) 18 (33)
3 71 (57) 37 (67)
METAVIR ﬁbrosis score 0.004
d
0 18 (14) 1 (2)
1 33 (26) 11 (20)
2 46 (37) 18 (33)
3 19 (15) 13 (24)
4 9 (7) 12 (22)
BMI (kg/m
2)
a,b 27 28 0.018
c
Assigned treatment duration
e 0.033
d
24 weeks 94 (75) 32 (58)
48 weeks 31 (25) 23 (42)
Values given in parentheses are percentages.
aMean.
bOne patient did not have data available for BMI.
cWilcoxon rank-sum test.
dFishers exact test.
eWhen the 12 patients (ﬁve from 24-week therapy and seven
from 48-week therapy) who withdrew early (before week
12) due to poor tolerance or adverse events are excluded,
this factor loses its signiﬁcance (P = 0.167).
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Fig. 1 Sustained virological rates according to genotype
and METAVIR ﬁbrosis score There was a signiﬁcant inter-
action between genotype and cirrhosis (F4) (P = 0.027).
P-value was derived from the cross-product of genotype and
cirrhosis in a multivariate logistic regression model of SVR
including cirrhosis (presence/absence), treatment group,
BMI and genotype.
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Chronic hepatitis C: SVR genotype 2 vs 3 55with the 18% F3 plus only 6% F4, and 18% of patients with
METAVIR ﬁbrosis score of ‡3 in the studies of Zeuzem et al.
[8] and Mangia et al. [11], respectively. In these two studies,
demonstrating an association between baseline viral load
and SVR among genotype 3, the focus was on courses of
therapy of £24 weeks. In the study by Von Wagner et al.
[12], the group treated for 16 weeks with genotype 3 and a
high baseline viral load, had a poorer response.
Most importantly, during the development of our MLR
analysiswedidnotdichotomizevariablessuchasﬁbrosisscore
and baseline viral load as was done in previously mentioned
studies of patients with genotype 2 and 3. This analytical
approach allowed for improved statistical power and data-
driven exploratory analysis rather than arbitrarily choosing
non-data-driven cut-off points to dichotomize variables.
Our ﬁnding of an interaction between genotype and
cirrhosis is limited by the sample size of 21 patients with
cirrhosis in our study. Of course there are problems with
inter-observer variability for the histological scoring of liver
biopsies. This is less of a problem in staging of ﬁbrosis
compared with grading of activity especially with expert
pathologists [26]. However, one would expect that any
variability in identifying cirrhosis would occur equally in
patients with genotype 2 or 3. As the power was robust, it is
unlikely that this represents a type 1 statistical error.
Although our sample size is small, it is larger than the
number of patients with advanced ﬁbrosis in the trials listed
above speciﬁcally addressing the treatment of genotype 2
and 3 infections. Because of the published recommendations
suggesting that a pretreatment liver biopsy does not need to
be performed in those patients with genotype 2 and 3 there
is a paucity of data available from other clinical studies to
address the interaction between genotype 3 and ﬁbrosis [27].
Regardless of this, our ﬁndings will need to be conﬁrmed in
subsequent studies with a larger population.
The precise pathophysiological mechanism explaining the
difference in SVR among patients with cirrhosis and geno-
type 2 vs genotype 3 is uncertain. Yet this may be explained
in part by the different early viral dynamics between the two
genotypes in response to antiviral therapy, especially among
those with advanced ﬁbrosis. Early decreases in HCV viral
load have been shown by several investigators to be an
independent predictor of subsequent SVR to antiviral agents
[9,28–30]. Hepatic ﬁbrosis has been demonstrated to be
associated with a slowing in the decline in HCV-RNA within
the ﬁrst 24 h of interferon therapy [31], and lack of ﬁbrosis
is an independent predictor of rapid virological response [9].
Genotype 2 infections are associated with a more rapid, free
virion clearance rate, better inhibition of viral replication
and enhanced killing of HCV-infected cells in response to
IFN therapy [14,31]. Even though a genotype 2-infected
patient may have advanced hepatic ﬁbrosis, the high IFN
sensitivity of genotype 2 may be able to overcome the neg-
ative impact of ﬁbrosis. In comparison, among genotype 3
infections the viral killing in association with antiviral
therapy may not be able to overcome the inﬂuence of hepatic
ﬁbrosis.
Current recommendations for the treatment of genotype 2
and 3 infections do not include pretreatment liver biopsy.
The most recent NIH recommendations state that as the
favourable response to current antiviral therapy that occurs
in more than 70% of patients infected with genotype 2 or 3,
it may not always be necessary to perform a liver biopsy
[27]. Our data would support this recommendation for those
with genotype 2 infections, yet in genotype 3 infections a
pretreatment liver biopsy would yield important information
on the patients subsequent response to antiviral therapy
and perhaps question their appropriateness for shorter
courses of therapy. Although rapid virologic response is also
a valuable tool predicting ultimate SVR among genotype 3
patients, it may not alleviate the need for pretreatment liver
biopsy. In order to provide patients with subsequent infor-
mation about the likelihood of achieving a clinical cure, they
need to endure a minimum of 4 weeks of therapy [9,11,12].
In conclusion this study demonstrates an interaction be-
tween genotype and cirrhosis, where patients with genotype
3 and cirrhosis respond less well to therapy than those with
genotype 2 and cirrhosis. If these ﬁndings are conﬁrmed in a
larger population, patients with genotype 3 infections may
beneﬁt from pretreatment liver biopsies in order to determine
their degree of hepatic ﬁbrosis and likelihood of subsequent
response to antiviral therapy. Whether patients with geno-
type 3 and advanced ﬁbrosis may beneﬁt from more pro-
longed courses of peg-IFN and ribavirin also needs further
examination.
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